Introduction: Smokeless tobacco products such as snuff and snus are used worldwide. However, little is known about the systemic and cardiovascular toxicity of smokeless tobacco exposure. Methods: Biomarkers of endothelial activation and injury, immune functions, platelet activation and insulin resistance were measured in 8-week old male C57BL/6 mice exposed to commercial snuff, CRP-2 reference snuff, commercial snus, CRP-1 reference snus, and nicotine in drinking water (100 µg/mL) for 4, 12, and 24 weeks. Results: Twenty-four weeks of exposure to smokeless tobacco products or nicotine significantly decreased the levels of circulating Flk
Introduction
Approximately 1.3 billion people use tobacco products globally. 1 Tobacco use accounts for more than 5 million deaths annually. Twelve percent of all death in people aged 30 years and over are attributed to tobacco usage, 2 and 29% of deaths in tobacco users are ascribed to cardiovascular disease (CVD). [2] [3] [4] Although, prevention, effective therapies (e.g. antihypertensive and cholesterol lowering drugs), and change in lifestyle have decreased the age adjusted death rates due to cardiovascular disease over the last 5 decades, 5 tobaccoattributable mortality is still increasing and is projected to result in >8 million deaths per year by 2030. 2, 3 Recognition of the adverse health effects of smoking on CVD, stroke, chronic obstructive pulmonary disease (COPD), and cancer 6, 7 has led to a steady decrease in the number of smokers in the United States in the last few years. 2, 7, 8 Nevertheless, usage of smokeless tobacco (ST) products (snuff, snus, naswar, gul, gutka, etc.) is increasing globally. 1, 9 Currently, approximately 3% of the adults in the United States use ST and snuff is the most commonly used ST in the United States. Approximately 7% of American Indians and Alaska natives use ST. 1, 10 In Scandinavian countries such as Sweden and Norway, nearly 30% of males use ST, primarily snus. 1, 10 In comparison with smokers, ST usage is associated with a lower incidence of lung cancer, oral cancer, COPD, and chronic inflammatory diseases. 11 However, data from epidemiological studies on ST and CVD are contradictory and inconclusive. A majority of studies conducted in Sweden did not find an association between ST usage (mostly snus and snuff) and nonfatal and fatal myocardial infarction (MI). 12, 13 Nevertheless, a meta-analysis 14 and a 19 years follow-up study of Swedish construction workers showed an increase in fatal MI in ST users. 15 The INTERHEART study, which was a case controlled study of 27 089 participants across 52 countries, showed that ST usage was associated with increased risk of acute MI. 16 But, in the United States, the first National Health and Nutrition Examination Survey (NHANES) epidemiological follow up study found no association between ST use and all-cause CV mortality. 17 On the contrary, the Cancer Prevention Study I (CPS-I) and Cancer Prevention Study II (CPS-II) showed that current ST use is associated with an increased hazard ratio for CVD mortality. 18 An association between ST usage and a modest increase in the risk of stroke mortality has also been observed in studies from the United States and Sweden. 18, 19 Assessment of the effects of ST on the risk factors of CVD has also led to inconsistent results. In a study of 2840 adult males, it was observed that ST users had a 2.5-fold increase in the risk of hypercholesterolemia. 20 In an independent study, chewing tobacco was associated with a significant increase in serum triglycerides and a decrease in HDL. However, no association between ST usage and lipoprotein profiles was observed in a cohort of baseball players and firefighters. 21, 22 A modest increase in the risk of developing hypertension in current ST users has been reported in a Swedish study, 23 whereas no difference in systolic and diastolic blood pressure was observed in nested case-control studies in the United States. 22, 24 The limited data available from human studies do not show an association between ST usage and inflammation or ST usage and thrombosis. 1 The odds ratio for developing metabolic syndrome and type-2 diabetes was found to be significantly increased in two Swedish studies. 25, 26 However, in the MONICA cohort, ST usage did not increase the odds ratio for developing type 2 diabetes. 24 Disagreement in epidemiological studies could stem from a variety of confounders including the heterogeneity of ST products and their constituents, duration of ST usage, genetic factors, and differences in lifestyle. Therefore, studies in experimental animals are required to examine the cardiovascular toxicity of ST products. Chronic exposure to nicotine in mice has been shown to induce angiogenesis and accelerate tumor growth and atherosclerosis, 27, 28 however, to the best of our knowledge, no studies have assessed whether ST products are causally involved in increasing the risk factors for CVD in experimental animals. Hence, using a well-controlled mouse model, we performed a comprehensive evaluation of the effects of ST products to identify sensitive and robust biomarkers of systemic injury caused by exposure to ST.
Methods
Eight-week old male C57BL/6 mice were exposed to nicotine (100 µg/ mL in tap water containing 2 µM saccharine), or ST extracts: CRP1 snus-Coresta Reference Product-1; Camel robust snus, CRP2 moist snuff-Coresta Reference Product-2; and Copenhagen long cut moist snuff containing 100 µg/mL nicotine levels in tap water containing saccharine (2 µM; 0 calories) for 4-24 weeks. Biochemical parameters were measured as described under Supplementary Materials.
Results

Levels of Nicotine and Its Metabolites in Smokeless Tobacco Exposed Mice
To examine whether exposure to ST affects the water intake, we measured water consumption in mice at baseline and after 1, 3, and 6 months of exposure to ST or nicotine. Water consumption in control mice was comparable with water consumption in C57BL/6 mice as described before. 29 As shown in Supplementary Figure 1 , water intake in ST exposed mice was comparable with nicotine-fed mice and controls. Next, we assessed the biomarkers of exposures by quantitating the levels of nicotine and its metabolites cotinine and 3-HC in the plasma and urine of mice exposed to ST and nicotine for 24 weeks. As shown in Figure 1A , traces of nicotine, cotinine and 3HC were detected in the plasma and urine of control mice. Nicotine was also detected in the urine of ST-(snus-CRP1 and Camel; and snuff-CRP2 and Copenhagen) or nicotine-exposed mice. However, cotinine and 3-HC were abundant in the plasma and urine of ST and nicotine exposed mice ( Figure 1A ). This could be attributed to the faster metabolism of nicotine in mice (plasma nicotine t 1/2 ~6-7 min) than humans (plasma nicotine t 1/2 ~2 h). 30 The total nicotine equivalent (nicotine + cotinine + 3HC) in the urine of nicotine or ST-exposed mice are provided in Figure 1A 
Metabolites of Aldehydes and Metals in Smokeless Tobacco Exposed Mice
Volatile organic compounds (especially aldehydes) are abundant in tobacco smoke and cardiovascular toxicity of smoking, at least in part, may be attributable to these aldehydes. 31 High levels of aldehydes have been detected in both new (Marlboro/Camel Snus) and conventional (General Snus, Snuff, and Long Cut) ST. 32 To examine the contribution of aldehydes in cardiovascular toxicity of ST products, we measured the metabolites of saturated (formaldehyde and acetaldehyde) and unsaturated aldehydes (acrolein and crotonaldehyde) in the urine of mice exposed to ST or nicotine for 24 weeks. As shown in Figure 1B , exposure to ST or nicotine had no effect on the levels of formate, the carboxylic acid metabolite of formaldehyde, whereas exposure to CRP-1 snus significantly decreased the levels of acetate, the carboxylic acid of acetaldehyde. Exposure to ST and nicotine did not affect the levels of mercapturic acids of acrolein (3-HPMA) and crotonaldehyde (HPMMA; Figure 1C ) in the urine. High levels of metals have been detected in ST and cigarette smoke. 33 However, our data show that levels of chromium, nickel, arsenic, cadmium, and lead by ICP-MS in the urine of mice exposed to ST or nicotine for 24 weeks were comparable with controls (Supplementary  Table 2 ). Collectively, these data suggest that exposure to snus or snuff does not affect the systemic levels of aldehydes and metals.
Toxicological Screening of Smokeless Tobacco Exposed Mice
Twenty-four weeks of exposure to snus, snuff, and nicotine did not affect body (Supplementary Figure 3) and organ weights (data not shown), circulating levels of liver enzymes, creatinine, total protein, albumin, and LDH ( Table 1 ), suggesting that ST products do not cause systemic toxicity. Plasma cholesterol, and triglycerides in all the ST and nicotine-treated mice were also comparable with controls suggesting that ST products do not affect plasma lipoproteins in mice.
Effect of Smokeless Tobacco on Endothelial Activation and Injury
To examine whether ST exposure induces cardiovascular injury, we measured the levels of endothelial progenitor cells (EPCs) in the peripheral blood. Low levels of EPCs are associated with increased cardiovascular disease 34 ; and could predict future cardiovascular events. 35 Our data show that 24 weeks of exposure to snus (CRP-1 and Camel) and snuff (CRP-2 and Copenhagen) decreased the levels of circulating EPCs Flk + (KDR)/Sca + by 45-55% (p < .05; Figure  2A ). Levels of EPCs in the bone marrow of ST exposed mice were comparable to controls (data not shown). Similar to ST products, 24 weeks of exposure to nicotine also decreased blood EPCs by 45% (p Figure 1 . Mass spectroscopic analyses of the metabolites of nicotine and aldehydes in the plasma and urine of smokeless tobacco (ST)-exposed mice. Mice were exposed to nicotine or ST (100 µg/mL nicotine in drinking water containing 2 µM saccharine) for 24 weeks. (A) LC-MS/MS analyses of nicotine and its metabolites in the plasma (n = 10/group) and urine (n = 5/group) as described under Methods. Protein-free filtrate was applied on UPLC and eluates were analyzed online using multiple reactions monitoring (MRM) transition (Supplementary Table 1 ). Representative elution profiles of 3-HC, nicotine, and cotinine are illustrated in panels I-III, respectively. Panel IV shows the abundance of nicotine, cotinine, 3HC, and total nicotine equivalent (nicotine + cotinine + 3HC) in the plasma of ST exposed mice. Levels of nicotine and its metabolites in the urine of ST exposed mice are shown in panel V as described under Methods. Samples were applied on UHPLC and eluates were analyzed for the MRM traces. (B) GC-MS analyses of the metabolites of formaldehyde (formate) and acetaldehyde (acetate) in the urine as described under Methods. Representative elution profiles of formate and acetate and their 13C analogs are illustrated in panel I. Panels II and III show the abundance of aldehyde metabolites in the urine of ST exposed mice. (C) LC-MS/MS analyses of the metabolites of acrolein (3-HPMA) and crotonaldehyde (HPMMA) in the urine. Panels I and III illustrate the representative elution profiles of 3-HPMA and HPMMA, and panels II and IV show the abundance of 3-HPMA and HPMMA, respectively in the urine of ST exposed mice. Values are mean ± SEM. *p < .05 versus control mice.
< .05). However, blood EPC levels in mice exposed to ST or nicotine for shorter duration (4 and 12 weeks) were comparable with controls (data not shown). Together, these data suggest that prolonged exposure to ST or nicotine results in endothelial injury.
To assess the effect of ST and nicotine on endothelial activation, we measured the levels of endothelial microparticles (MP) in the peripheral blood of ST and nicotine exposed mice. Increased levels of endothelial MP have been observed in cardiovascular disease with impaired endothelial functions such as coronary artery disease and stroke. 36, 37 We + ; data not shown). Total endothelial MP in mice exposed to ST or nicotine for 24 weeks were also comparable with controls. However, levels of activated endothelial MP and EPCderived MP were decreased by 25-35% (p < .05) in mice exposed to ST or nicotine for 24 weeks ( Figure 2B ). To further examine the effect of ST and nicotine on endothelial activation, we measured the levels of circulating adhesion molecules and von Willebrand factor (vWF). As shown in Table 1 , abundance of soluble adhesion molecules-endothelial selectin (sE-Selectin) and soluble intercellular adhesion molecules-1 (sICAM-1), endothelin-1, and vWF in the plasma of ST and nicotine exposed mice (for 24 weeks) were comparable with controls. Collectively, these data suggest that exposure to ST does not lead to endothelial activation.
Immunological Effects of ST
Smoking induces systemic inflammation, and proinflammatory cytokines are strong predictors of future cardiovascular events. 38 However, little is known about the effect of ST on immune functions. We observed that 4 weeks of exposure to ST or nicotine did not affect CBC (data not shown). However, as shown in Figure 3A , 12 weeks of exposure to snus (CRP-1 and Camel), snuff (CRP-2 and Copenhagen) and nicotine decreased the levels of white blood cells (WBC) by 40-55% (p < .05), lymphocytes by 50-60% (p < .05), and monocytes by 30-40% (p < .05), suggesting that ST could affect both innate and adaptive immunity. Twelve weeks of exposure to Camel snus also decreased neutrophil levels in blood by 50% ( Figure 3A ; p < .05). Similar changes in the levels of immune cells were observed after 24 weeks of exposure to ST or nicotine (data not shown).
To further characterize and quantify the effect of ST and nicotine on immune cells, we analyzed peripheral blood cells by flow cytometry. Cells were gated as illustrated in Figure 3B . Time course analyses Figure 3C ). CRP-1 snus, CRP-2 snuff, and nicotine did not affect the abundance of these cells. Levels of all the other immune cells following 4 weeks of exposure to various ST and nicotine were comparable with controls. Prolonged exposure (12 Figure 3D ). Measurement of cytokines in the plasma of mice exposed to ST showed 24 weeks of exposure to ST or nicotine showed suppression of the circulating levels of interferon γ (IFNγ) by 50-70% (Table 1) . Camel snus and CRP-1 snuff also decreased the levels of IL-6 in these mice. However, Copenhagen snuff increased the circulating RANTES (CCL5) levels by 2.2-fold and TNFα levels by 1.4-fold (Table 1) . TNFα levels were also increased by 55% in nicotine exposed mice (Table 1 ). This was accompanied by a five-to sevenfold increase in the hepatic expression of TNFα in Copenhagen snuff and nicotine exposed mice (Supplementary Figure 4) . Exposure to CRP-2 snuff and Camel snus also increased the expression of TNFα in the liver by two-to fourfold; however, the plasma TNFα levels in these mice were comparable with controls. Nonetheless, plasma levels of TNFα in Camel snus exposed mice were comparable with controls (Table 1) . ST or nicotine did not affect the levels of IL-10, IL-17, KC (CXCL 1), MCP-1 (CCL2), Eotaxin, and VEGF (Table  1) . Taken together, these data suggest that chronic exposure to snuff, snus, and nicotine depletes immune cells, and that some ST products differentially regulate the abundance of hepatic and circulating cytokines. 
Effect of ST on Platelet Activation and Thrombosis
Flow cytometric analyses showed that 24 weeks of exposure to ST or nicotine does not affect the levels of platelet-leukocyte aggregates in the blood (Table 1) . Similarly, exposure to ST or nicotine for 4 or 12 weeks did not alter the formation of platelet-leukocyte aggregates (data not shown). Plasma levels of platelet factor 4 (PF4, CXCL4), a chemokine released from the α-granules of activated platelets 39 and PAI-1 (Serpin E1), principal inhibitor of tissue plasminogen activator and a risk factor for thrombosis and atherosclerosis 40 were also not affected by ST or nicotine (Table 1) . Collectively, these data suggest that chronic exposure to ST and oral nicotine does not affect platelet activation and circulating markers of thrombosis in mice.
ST and Soluble Matrix Metalloproteinases
Circulating levels of matrix metalloproteinases (MMPs) are associated with increased risk for atherosclerosis. 41 Our data show that exposure to ST or oral nicotine for 24 weeks did not affect the levels of sMMP-9 (Table 1) . However, exposure to Camel snus and CRP2 snuff decreased the levels of sMMP-3 by 43% and 66%, respectively whereas levels of these proteins in CRP-1 snus, Copenhagen snuff or nicotine-exposed mice were comparable with controls (Table 1) .
ST and Insulin Resistance
Cigarette smoking and high consumption of moist snuff (150 g/ week) has been linked with an increased risk for type 2 diabetes. 26 Some, but not all studies show that smoking is associated with increased insulin resistance. 26, 42, 43 We observed that fasting blood glucose, insulin, and homeostatic model assessment of insulin resistance (HOMA-IR) levels in mice exposed to ST or nicotine for 23 weeks were comparable with controls (Supplemental Figure 3) . When subjected to glucose tolerance test (GTT), the ST or nicotine exposed mice (for 23 weeks) showed the glucose clearance rate comparable with controls. These data suggest that chronic ST or nicotine exposure does not lead to insulin resistance in mice.
Discussion
Although the use of ST products has been variably linked to an increase in cardiovascular mortality and CVD risk, 44 data on the systemic effects of these products are limited and conflicting. As a result, it remains unclear whether and how recurrent use of these products results in tissue injury and which specific constituents, if any, may be responsible for the potential harm induced by ST product use. Since such questions are difficult to address in human observational studies, we examined the effects of snus and snuff exposure in a wellcontrolled murine model, to determine how exposure to ST products affect systemic inflammation and insulin sensitivity as well as endothelial injury. We found that chronic exposure to ST products did not affect platelet activation, whole-body insulin sensitivity, or plasma lipoprotein levels, but it led to a selective suppression of circulating EPCs and endothelial MP; both CD19 + B cells and CD11b + monocytes were markedly suppressed as well, as were the CD4 + and CD8 + T cells. Exposure to ST products also led to a consistent suppression of plasma IFN-γ levels and product-specific changes in plasma TNF-α and IL-6 levels. Collectively, these findings reveal unique and characteristic features of the systemic toxicity of ST products, and have implications for understanding the potential effects of ST product use on the cardiovascular system and immune responses. These are also very sensitive markers of ST toxicity, because in mice they appear at the plasma total nicotine equivalent comparable to lower end of ST exposures in humans.
The mean urinary nicotine level in ST or nicotine-fed C57BL/6 mice (99-323 µg/mmol creatinine) in our study was 4-to 12-fold higher than the mean urinary nicotine level in humans using snus for at least a year (26 µg/mmol creatinine) and 3-fold higher than chronic smokers (41 µg/mmol creatinine). 45 Similarly, mean urinary cotinine level in ST or nicotine-exposed mice (804-1293 µg/mmol creatinine) was five to eight-fold higher than chronic snus users (159 µg/mmol creatinine) and smokers (161 µg/mmol creatinine), 45 and 9.6-fold higher than chronic users who consumed 25 mg snus/day. 46 The total nicotine equivalent recovered in the urine of nicotine or ST-exposed mice (0.8-1.5 mg/day/kg body weight; Supplementary Figure 2 ) was 3-6 times higher than the total nicotine equivalent excreted/day in the urine of humans (assuming the average body weight of tobacco products users to be 75 kg) using ≥2 cans of moist snuff/week for ≥3 years (0.25 mg/day/kg body weight), 47 smoking ≥10 cigarettes/ day for ≥3 years (0.25 mg/day/kg body weight), 45 smoking ≥20 cigarettes/day (0.36 mg/day/kg body weight), 48 and using transdermal nicotine (releasing 1.5 mg nicotine/h). 49, 50 Together, these data suggest that the dose of nicotine used in mice in our study was appreciably higher than humans using tobacco products including snus. The dose of oral nicotine used in our study has been shown to induce angiogenesis, and accelerate tumor growth and atherosclerosis in apoE-KO mice (on C57BL/6 background). 27, 28 However, despite the significantly higher daily consumption of nicotine than humans using tobacco products, only traces of nicotine were detected in the plasma of ST or nicotine exposed mice. This could be attributed to faster nicotine metabolism in mice than humans (plasma nicotine t 1/2 ~6-7 min in mice and t 1/2 ~2 h in humans). 30 Because nicotine concentrations in the plasma due to intermittent ingestion in drinking water are difficult to measure as they are likely to be variable, we also fed mice nicotine by gavage. As shown in Supplementary Figure 5 , when fed 10 µg nicotine, we found that plasma nicotine concentration was ~5 ng/mL within 60 min of nicotine ingestion. Gavage with 100 µg nicotine yielded plasma nicotine levels of ~20 ng/mL within 60 min, which is nearly twice the level achieved by chewing nicotine gum (9-11 ng nicotine/ mL) and in the range of nicotine 2 min after each cigarette (8-27 ng/ mL) in humans. 51 In humans, 1 g of snus leads to a plasma nicotine concentration of 14-15 ng/mL, whereas 4 mg nicotine polacrilex chewing gum leads to a plasma concentration of 13 ng/mL. 52 The mean time to peak is between 37 and 40 min, which is comparable to our results with mice. Thus, mice drinking ~1 mL of water containing 100 µg/mL nicotine (~10 bouts of 10 µg) are likely to achieve acutely plasma concentrations similar to the lower end of human exposure to smokeless tobacco, however, as described below, the total dose of nicotine ingested by the mice over a day is likely to be five-to eightfold higher than human snus users.
Plasma cotinine levels in mice chronically exposed to ST or nicotine were 5-to 10-fold lower than plasma/serum cotinine concentration in smokers and humans using ST products. [53] [54] [55] The lower plasma cotinine levels in ST or nicotine exposed mice could be ascribed, at least in part, to the 6 h fast before euthanasia and blood collection. This was necessary because our protocol requires fasting blood samples for the measurement of plasma cholesterol, triglycerides, and several other biochemical indices of cardiovascular and metabolic toxicity.
To assess cardiovascular injury due to ST use, we examined changes in indices of endothelial injury and damage. Previous studies have shown that the endothelium is particularly vulnerable to the effects of tobacco smoke. In smokers, endothelial dysfunction is the earliest sign of injury, which precedes morphological changes in the vessel wall. 56 A dysfunctional endothelium affects blood pressure regulation, atherogenesis, heart failure, arrhythmogenesis, and plaque stability.
57, 58 Smoking injures endothelial cells and blood vessels isolated from smokers show degenerative changes in the endothelium, including blebbing, contraction, and opening of gap junctions.
59
These structural changes are preceded by functional impairment. In humans, smoking acutely causes endothelial cell damage 60 and diminishes endothelium-mediated relaxation. 61 A particularly sensitive index of smoking-induced injury is the depletion of circulating EPC levels. The EPC in blood arise from the bone-marrow and have been found to be important in maintaining endothelial health and promoting tissue repair after injury. The mobilization and homing of EPCs can be impacted by exogenous factors including advanced age, disease, and an unhealthy lifestyle, 37, [62] [63] [64] [65] and, therefore changes in EPC levels are reflective of endothelium health. Circulating EPC levels are particularly sensitive to toxins and inhaled pollutants. We have found that exposure to airborne particulate matter (PM) decreases EPC levels in humans and mice 66 and that exposure to acrolein, reversibly suppresses EPC levels in mice. 67 Significantly, EPC levels in blood are lower in smokers than in nonsmokers, 65,68 and even a brief (30 min) exposure to second-hand smoke depletes EPC levels in nonsmokers. 62 In agreement with these reports, we found that long-term exposure to ST products was associated with suppressed EPC levels in blood. Unlike the effects of inhaled pollutants (tobacco smoke, acrolein, PM), the effects of ST exposure were not rapid and took 24 weeks to suppress circulating EPC levels. A decrease in the levels of these cells is suggestive of significant deficiencies in endothelial repair and wound healing due to prolonged exposure to ST products. Even though the constituents of ST products that suppress EPC levels remain unclear, our observation that exposure to nicotine led to a similar decrease in circulating EPCs suggests that nicotine present in ST products may be an important contributor to this effect. Because EPCs promote angiogenesis, our data showing that ST products and nicotine exposure deplete circulating EPCs suggest that they can inhibit angiogenesis. This is in contrast to previous studies, which report that nicotine is proangiogenic and that it could promote neovascularization of atherosclerotic lesions and tumors. 27 A proangiogenic effect of nicotine, therefore, is difficult to reconcile with its ability to suppress circulating EPC levels. However, it could be speculated that the effects of nicotine on other angiogenic factors overcomes its effects on EPCs, but further studies are required to assess how nicotine-and ST-induced EPC depletion affects endothelial health and wound healing.
To examine endothelial changes in greater detail, we measured the levels of MP that are released from activated or apoptotic endothelial cells. 69 These MP are a sensitive measure of vascular injury.
70,71
Recent work has shown that plasma levels of lung endothelial MP are elevated in healthy smokers and that this increase in MP precedes changes in pulmonary function, indicating that changes in MP levels are a more sensitive and early index of smoking-induced lung injury than can be detected by spirometry. 72 However, our data showing that even chronic and prolonged exposure to ST did not increase the levels of endothelial MP suggest that ST does not cause endothelial activation and apoptosis. This is further supported by our data showing that the levels of soluble adhesion molecules, endothelin, and vWF in the plasma were not affected by exposure to ST products. This is in contrast to cigarette smoke exposure, which increases the expression of ICAM-1 and ELAM-1 on endothelial cells 73 ; changes that suggest increased endothelial adhesiveness. Thus, exposure to ST products does not seem to cause endothelial injury to the extent seen with cigarette smoking. Nonetheless, we did observe a decrease in the circulating levels of activated endothelial MP as well as MP derived from EPCs. Because circulating levels of EPCs are decreased in ST exposed mice, the decrease in EPC MP is likely to be reflective of EPC pauperization. In contrast, reasons for the decrease in activated endothelial MP remain unclear, but may relate to impaired ability of the endothelium to generate MP, which could contribute to increased endothelial injury, but preventing the release of MP carrying injurious cargo away from the cell.
In addition to endothelial changes, we also observed changes in immune cells and cytokines in ST exposed mice. Previous work has shown that tobacco products, especially cigarette smoke, affect a broad spectrum of immune functions impacting both innate and adaptive host immunity. 74 Blood granulocytes, primarily neutrophils are significantly higher in smokers than nonsmokers, and return to normal after smoking cessation. 75, 76 However, the effects of smoking on monocytes and lymphocytes in smokers are inconsistent. 77 Little is known about the impact of ST products on immune responses, although in a study of 1061 professional baseball players, ST use was found to be associated with a significant decrease in WBCs. 22 Our observation showing that chronic exposure to ST or oral nicotine decreases total WBC counts in mice is consistent with the results of this study and support the concept that nicotine in ST products has immunosuppressive effects. Because, unlike smoking, ST exposure did not increase the levels of neutrophils, it appears that high levels of neutrophils in smokers may be due to the immune stimulating effects of combustion products in cigarette smoke.
Our observation that exposure to snuff and snus depletes monocytes in blood suggests that ST could affect innate immunity as well. These data are in agreement with a recent report showing that blood monocyte counts are decreased by 65% in ST users.
78 How smoking affects blood monocyte abundance is unclear. Jensen et al. 79 have reported that blood monocyte counts are significantly lower in healthy chronic smokers than never smokers and smoking cessation significantly increases the blood monocytes, but in contrast, the work of Noble and Penny 80 shows that smoking increases monocyte abundance in the blood. This disparity could stem from a variety of reasons such as differences in the duration and frequency of exposure, levels of combustion products in different brands, genetic factors and lifestyle differences in different populations. Regardless, using CBC as well as flow cytometric data, we found that snus and snuff consistently decrease blood levels of monocytes in mice. Moreover, because nicotine exposure was sufficient to cause monocytopenia, comparable with ST exposure, it appears that depletion in blood monocytes by ST, at least in part, is driven by nicotine. ST products as well as nicotine depleted both the proinflammatory Ly6C high and anti-inflammatory Ly6C low monocytes in the same proportions, suggesting the ST induced inflammatory responses are not governed by the abundance of a specific class of monocytes. Further studies are required to examine whether ST products inhibit the release of monocytes from the myoblasts in the bone marrow or whether low levels of monocytes are due to greater tissue recruitment of these cells in animals exposed to ST products.
In addition to monocytes, we also observed that chronic exposure to ST 81 The decrease in CD4 + T cells in these subjects is proportional to the number of cigarettes smoked per day. In contrast, in Caucasians, smoking increases the abundance of CD4 + T cells. 77, 81 Additional studies are required in ST users to examine whether oral tobacco products affect the abundance and/or functions of T cells and whether the observed decrease in T cells upon ST exposure is associated with immunosuppression and decreased ability to clear infectious agents.
Little is known about the effect of smoking or ST usage on the abundance of circulating B cells in humans. Our observation that exposure to snuff, snus, and oral nicotine led to a depletion of B cells in mice suggests that ST exposure may affect adaptive immunity by diminishing antibody production and/or secretion. These changes may enhance the susceptibility to infection in ST-exposed individuals. Moreover, the deficiency of T cells in ST-exposed subjects may diminish the T-cell dependent activation of B cells and compromise humoral responses. Chronic exposure to cigarette smoke in mice increases the susceptibility to influenza and sarcoma viruses 77 ; and in humans it significantly decreases serum immunoglobulin levels, and antibody response to various antigens. 77 However, despite decreased immunoglobulin, the levels of autoantibodies in smokers are increased, especially for antinuclear rheumatoid factors.
82
Consistent with lymphocyte and monocyte depletion, our data also showed that exposure to snuff and snus significantly decreases the levels of IFNγ in the plasma. These observations are in agreement with the in vitro studies which show that ST extracts decrease the expression of IFNγ in T-cells. 83 Because we observed that exposure to nicotine is sufficient to decrease the levels of IFNγ in the plasma, it appears that ST-induced depletion of IFNγ is driven by nicotine. Alternatively, the lower levels of IFNγ in the plasma of ST exposed mice could be due to the lower abundance of lymphocytes and monocytes in these animals. Petro et al. 83 also observed that ST decreased the expression of IL-6 and increased the transcription of IL-2 in T cells, whereas Biswas et al., reported that ST extracts do not affect the levels of IL-6 in mononuclear cells. 78 Although, we did not measure IL-2, the levels of IL-6 in the plasma of nicotine-treated mice were comparable with controls, suggesting that nicotine does not affect IL-6 production. However, exposure to two ST brands (Camel and CRP2) resulted in the suppression of IL-6 levels, suggesting that non-nicotine constituents of these brands, not present in other brands, may have important immunosuppressive effects.
Despite a decrease in the levels of leukocytes in the blood, we observed that 24 weeks of exposure to Copenhagen snuff or oral nicotine significantly increased the levels of TNF-α in the plasma; however plasma TNF-α levels in CRP-1 and Camel snus and CRP2 snuff exposed mice remain unchanged. Because nicotine was sufficient to induce TNFα formation, it appears that some of the constituents of CRP-1 and Camel snus and CRP2 snuff inhibit TNF-α formation. The nicotine and Copenhagen snuff-induced TNF-α formation in our study is in agreement with the study by Avti et al., who showed that exposure to smokeless tobacco product (gutka) for 28 weeks leads to a 2-fold increase in plasma TNF-α levels in rats. 84 Exposure to nicotine for 90 days has also been reported to increase the serum levels of TNF-α, IL-1β, and IL-8 by 1.5-to 2.0-fold in LDL receptor-KO mice. 85 Serum levels of TNF-α and IL-1β are also significantly higher in active smokers than non-smokers. 86 In vitro, ST extracts increase the formation of TNF-α in blood mononuclear cells and macrophages. 78, 85 Such an increase in TNF-α levels by nicotine and some ST products could induce vascular inflammation and exacerbate atherosclerosis.
In summary, the results of our present study show that exposure to ST tobacco products has suppressive effects on a wide range of circulating blood cells including WBCs, EPCs, lymphocytes, monocytes, and T and B cells (Table 2) . We also observed a significant suppression of circulating endothelial MP. We found no changes in platelet activation, plasma lipoproteins, or systemic insulin resistance. Taken together, these findings uncover characteristic features of ST toxicity, which despite its mild nature, is indicative of increased susceptibility to infection, decreased clearance of infectious agents and deficiencies in endothelial repair and wound healing. Further in depth investigations are needed to understand how these changes relate to the overall risk of infectious and cardiovascular diseases as well as premature mortality.
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